Livzon Pharmaceutical Group Inc. Livzon Pharmaceutical Group Inc.

Livzon Pharmaceutical Group Inc.

000513

Rankning i aktier #4689
Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and... Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and established in 1985, is a biopharmaceutical enterprise operating across the entire spectrum of pharmaceutical activities, from research and development to manufacturing and commercialization. The company's operations encompass a diverse range of finished drug products, active pharmaceutical ingredients (APIs), and chemical intermediates, primarily serving the Chinese market while also engaging in international exports. Its pharmaceutical portfolio includes treatments such as Ilaprazole enteric coated tablets for duodenal ulcers and reflux esophagitis, Laprazole sodium injection for managing peptic ulcer bleeding, Leuprorelin Acetate Microspheres for injection, and Urofollitropin injection for anovulation and fertility support. Livzon also produces Perospirone Hydrochloride for schizophrenia, Anti-viral Granules targeting upper respiratory tract infections and influenza, and Shenqi Fuzheng Injection, which addresses general weakness, fatigue, spontaneous sweating, and vertigo, and provides supportive care for lung and stomach cancer patients. Beyond therapeutic drugs, Livzon Pharmaceutical Group develops and distributes a variety of diagnostic reagents. These include kits for detecting IgM/IgG antibodies to coronavirus, nucleic acid tests for human immunodeficiency virus type 1, antinuclear antibody test kits, interferon-gamma release assay kits, and rapid tests for mycoplasma pneumoniae IgM antibodies. The company's extensive offerings further extend to biochemical drugs, microbiological preparations, biologics, traditional Chinese medicine formulations, pharmaceutical raw materials, and antibiotics.
Aktiekurs
$3.90
Marknadsvärde
$3.17B
Förändring (1 dag)
-3.49%
Förändring (1 år)
-25.88%
Land
CN
Handel Livzon Pharmaceutical Group Inc. (000513)

Kategori

Healthcare
Vinst för Livzon Pharmaceutical Group Inc. (000513)
Vinst i Jun 2026 TTM: $353.39M
Enligt de senaste finansiella rapporterna från Livzon Pharmaceutical Group Inc. är företagets nuvarande vinst $353.39M. År 2024 hade företaget en vinst på $384.45M, en ökning jämfört med vinsten år 2023 som var $336.60M. Vinsten som visas på denna sida är vinsten före räntor och skatt, även kallad EBIT.
Vinshistorik för Livzon Pharmaceutical Group Inc. från 2001 till 2026
Vinst vid slutet av varje år
År Vinst Ändra
2026 (TTM) $353.39M -13.61%
2025 $409.07M 6.40%
2024 $384.45M 14.22%
2023 $336.60M -0.37%
2022 $337.86M -4.38%
2021 $353.32M -7.28%
2020 $381.07M 53.60%
2019 $248.09M 20.46%
2018 $205.95M -76.59%
2017 $879.92M 507.84%
2016 $144.76M 16.35%
2015 $124.42M 18.19%
2014 $105.27M 1.52%
2013 $103.69M 15.39%
2012 $89.85M 22.30%
2011 $73.47M -9.13%
2010 $80.85M -6.35%
2009 $86.33M 457.58%
2008 $15.48M -81.76%
2007 $84.91M 200.91%
2006 $28.22M 72.44%
2005 $16.36M -12.46%
2004 $18.69M -1.91%
2003 $19.06M 40.37%
2002 $13.58M 11.75%
2001 $12.15M 0.00%
Vinst för liknande företag eller konkurrenter
Företag Vinst Skillnad i vinst Land
$3.62B 923.75%
DE
$3.40B 863.51%
DE
$1.72B 387.73%
JP
$930.30M 163.25%
CH
$1.69B 378.97%
IN